Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth

Fig. 4

Anticancer effect mediated by CD::UPRT::GFP_AD-MSCs/5FC. Therapeutic AD-MSCs were cocultured with a U-251MG, U-251MG™ZR40, b U-87MG, U-87MG™ZR40, c U3008MG, U3020MG, U3054MG, U3117MG and d primary fibroblast cells. The cells were plated in 96-well plate in DMEM supplemented with 2% FBS. The therapeutic cells and target cells were mixed at ratios of 1 CD::UPRT::GFP_AD-MSC to 1, 5, 25, 10, 50 and 100 target cells. One day later, the culture medium was replaced with DMEM supplemented with 2% FBS in the presence or absence of 100 μg/mL 5FC. Seven days later, cell viability in the treatment conditions was evaluated spectrophotometrically by standard MTS assay. Cell viability (%) was defined as sample/control × 100%. Conditions without 5FC treatment served as controls. Conditions of no MSCs provide evidence that 5FC is non-toxic to the target cells. Data of biological quadruplicates presents as mean + SD

Back to article page